beta
Trial Radar AI
Clinical Trial NCT07266350 for Cervical Cancer Metastatic, Cervical Cancer Recurrent is not yet recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here.
One study matched filter criteria
Card View
Back to Search

A Non-interventional Registration Study of Monotherapy or Combination Regimens Based on Camrelizumab or Famitinib for the Treatment of Cervical Cancer 1,300 Open-Label Combination Therapy

Not yet recruiting
Clinical Trial NCT07266350 is an observational study for Cervical Cancer Metastatic, Cervical Cancer Recurrent and is currently not yet recruiting. Enrollment is planned to begin on 30 December 2025 and continue until the study accrues 1,300 participants. Led by Qi Zhou, this study is expected to complete by 30 December 2030. The latest data from ClinicalTrials.gov was last updated on 5 December 2025.
Brief Summary
This trial is a national multicenter, open-label, non-interventional study to observe and evaluate the safety and efficacy of monotherapy or combination regimens based on camrelizumab or famitinib in patients with cervical cancer.

This study included patients with cervical cancer who used monotherapy or combination regimens based on camrelizumab or famitinib. The administration regimens include but are not limited t...

Show More
Official Title

A Non-interventional Registration Study of Monotherapy or Combination Regimens Based on Camrelizumab or Famitinib for the Treatment of Cervical Cancer

Conditions
Cervical Cancer MetastaticCervical Cancer Recurrent
Other Study IDs
  • CZLL2025-042-001
NCT ID Number
NCT07266350
Start Date (Actual)
2025-12-30
Last Update Posted
2025-12-05
Completion Date (Estimated)
2030-12-30
Enrollment (Estimated)
1,300
Study Type
Observational
Status
Not yet recruiting
Arms / Interventions
Participant Group/ArmIntervention/Treatment
Cohort 1
camrelizumab
Camrelizumab
200mg IV Q3W
Cohort 2
famitinib
Famitinib
20mg QD PO
Cohort 3
camrelizumab +famitinib
Camrelizumab
200mg IV Q3W
Famitinib
20mg QD PO
Cohort 4
camrelizumab+others
Camrelizumab
200mg IV Q3W
Cohort 5
famitinib+others
Famitinib
20mg QD PO
Cohort 6
camrelizumab+famitinib+others
Camrelizumab
200mg IV Q3W
Famitinib
20mg QD PO
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
safety according to CTCAE v5.0
The safety of monotherapy or combination regimens based on camrelizumab or famitinib in patients with cervical cancer under real-world conditions. Per CTCAE v5.0, preferred term and grade will be documented.
From the first administration to 30 days after the end of the medication
Secondary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
real world ORR
It is defined as the sum of the proportions of patients with complete response (CR) and partial response (PR) based on investigator assessment from the initiation of monotherapy or combination regimens based on camrelizumab or famitinib to disease progression/recurrence or the start of new anti-tumor treatment.
from the initiation of monotherapy or combination regimens, per 6-8 weeks
overall survival
It is defined as the time from the start of the first treatment to death caused by any reason.
From date of treatment until the date of date of death from any cause, assessed up to 3 years
Participation Assistant
Eligibility Criteria

Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
Female
  1. Age ≥18 years old;
  2. Sign the informed consent form and voluntarily join this study;
  3. Patients with cervical cancer diagnosed by histopathology;
  4. Receive treatment with monotherapy or combination regimens based on camrelizumab or famitinib;
  5. It is necessary to agree to take effective contraceptive measures and avoid egg donation from the time of signing the informed consent form until 2 months after the last administration of camrelizumab, 3 months after the last administration of famitinib, or within the contraceptive period specified in the instructions of the last administration of other study drugs (whichever is longer).

If a patient has had menstruation but has not yet reached postmenopausal status (with no menstruation for a continuous period of ≥12 months and no other causes found except menopause), and has not undergone sterilization surgery (such as hysterectomy, bilateral tubal ligation or bilateral oophorectomy), the patient is considered to have fertility.

  1. There is already evidence indicating that the patient is a pregnant or lactating woman.
  2. Currently participating in any research involving intervention measures outside of regular clinical practice;
  3. The researcher determines other circumstances that are not suitable for inclusion in the study.
Qi Zhou logoQi Zhou
Study Responsible Party
Qi Zhou, Sponsor-Investigator, doctor, Chongqing University Cancer Hospital
Study Central Contact
Contact: Xingtao Long, 023-65075696, [email protected]
No location data.